ADMA Biologics Shareholders Approve Directors, Auditor and Executive Pay at Annual Meeting

ADMA Biologics (NASDAQ:ADMA) held its virtual Annual Meeting of Stockholders, with shareholders approving all three proposals presented by the company, including the election of two Class I directors, ratification of the company’s auditor and an advisory vote on executive compensation.

Adam Grossman, ADMA Biologics’ President and Chief Executive Officer, called the meeting to order and said the virtual format allowed the company “to be more inclusive and reach a greater number of stockholders.” The company designated Christopher Woods of American Election Services LLC as Inspector of Election for the meeting.

Quorum Established

Woods reported that 199,267,547 shares of ADMA Biologics common stock were represented at the meeting, either virtually or by proxy. The company had 232,324,283 shares of common stock issued, outstanding and entitled to vote, with each share entitled to one vote.

Based on the shares represented, Grossman said a majority of the outstanding shares entitled to vote were present, establishing a quorum and allowing the meeting to proceed.

The company’s secretary reported that the notice of the annual meeting, proxy statement, proxy card and annual report for the fiscal year ended Dec. 31, 2025, were made available electronically or by mail to stockholders of record as of April 8, 2026.

Directors Elected

Stockholders elected Alison Finger and Eduardo Rene Salas as Class I directors. Each will serve until the 2029 annual meeting of stockholders and until a successor is duly elected and qualified, or until an earlier resignation, removal or death.

• Alison C. Finger: 156,849,830 votes in favor; 19,376,842 votes withheld; 23,040,875 broker non-votes.
• Eduardo Rene Salas: 171,947,523 votes in favor; 4,279,149 votes withheld; 23,040,875 broker non-votes.

Grossman also introduced the company’s current directors other than himself: Steven Elms, Alison Finger, Jerrold Grossman, Lawrence Guiheen, Young Kwon and Eduardo Rene Salas. He also introduced Kaitlin Kestenberg, Chief Operating Officer and Senior Vice President, Compliance, and Paul Terence Kohler Jr., Chief Financial Officer and Treasurer.

KPMG Ratified as Auditor

Shareholders also ratified the appointment of KPMG LLP as ADMA Biologics’ independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.

The proposal received 198,655,040 votes in favor, 329,056 votes against and 283,451 abstentions. Grossman introduced Joe Zeni and Jennifer Turk of KPMG LLP during the meeting.

Say-on-Pay Proposal Approved

Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. The say-on-pay proposal received 168,169,866 votes in favor, 7,730,690 votes against and 326,116 abstentions.

Grossman said the final voting results would be reported in a current report on Form 8-K within four business days of the meeting. No shareholder questions were active through the web portal, and the meeting was adjourned following the completion of the voting business.

About ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.